托伐普坦治疗肝硬化难治性腹水的长期疗效

Long-term efficacy of tolvaptan in liver cirrhosis patients with refractory ascites

托伐普坦作为新一代口服的选择性血管加压素受体拮抗剂,已经成为欧洲、日本及中国等国家地区用于治疗肝硬化难治性腹水的理想用药,而且被美国食品药品监督管理局推荐用于治疗高容量性、正容量性低钠血症,然而不足的是,大部分实验研究及临床观察仅限于托伐普坦的短期疗效评估,不能充分证实长期应用的可行性,本文通过查阅近期文献着重论述口服托伐普坦在治疗肝硬化难治性腹水的长期疗效和安全性。

Tolvaptan as a new generation of oral selective vasopressin receptor antagonist,has become the ideal drug for patients with cirrhosis refractory ascites in many countries such as Europe,Japan and China,and has been recommended by the United States Food and Drug Administration for hyponatremia treatment of high capacity,positive capacity.However,most of the experimental studies and clinical observations are limited to the assessment of short term efficacy of tolvaptan,and can not adequately confirm the feasibility of its long term use.In this review,we focus on the long term efficacy and safety of oral tolvaptan in treatment of liver cirrhosis with refractory ascites by reviewing the recent literatures.